ivosidenib

isocitrate dehydrogenase (NADP(+)) 1 ; Homo sapiens







83 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34751786 Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. 2022 May 4 1
2 34871844 Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression. 2022 Jan 1 3
3 35154988 Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review. 2022 Jan 3
4 35190971 Systemic Therapy for Chondrosarcoma. 2022 Feb 3
5 35198955 The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma. 2022 4
6 35259259 FDA Approval Summary: Ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation. 2022 Mar 8 3
7 35296436 Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. 2022 Mar 13 3
8 35418865 Ag120-Mediated Inhibition of ASCT2-Dependent Glutamine Transport has an Anti-Tumor Effect on Colorectal Cancer Cells. 2022 4
9 35443108 Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. 2022 Apr 21 3
10 35460975 IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. 2022 2
11 35532213 Ivosidenib Boosts Azacitidine's Effectiveness in AML. 2022 May 9 1
12 33024987 Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. 2021 Apr 1 1
13 33119479 Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. 2021 Jan 1 4
14 33397455 Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML. 2021 Jan 4 1
15 33493146 Biliary cancer: gateway to comprehensive molecular profiling. 2021 Jan 1
16 33493392 Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies. 2021 May 1
17 33683991 Ivosidenib: an investigational drug for the treatment of biliary tract cancers. 2021 Apr 1
18 33709779 Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. 2021 Jun 3
19 33772143 Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. 2021 Nov 1
20 33799004 IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? 2021 1
21 33822485 PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. 2021 Jun 3
22 33832922 Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling. 2021 Apr 4
23 33836133 Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. 2021 May 8
24 33898313 IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. 2021 1
25 33932504 Practical considerations in screening for genetic alterations in cholangiocarcinoma. 2021 Sep 1
26 34071627 Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia. 2021 May 28 1
27 34188585 Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. 2021 1
28 34313176 Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome. 2021 Dec 2
29 34321251 Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. 2021 Oct 3
30 34554208 Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. 2021 Nov 1 6
31 34626563 Current and emerging therapies for advanced biliary tract cancers. 2021 Nov 1
32 34889359 What to use to treat AML: the role of emerging therapies. 2021 Dec 10 1
33 31028664 Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. 2020 Apr 5
34 31841594 Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. 2020 Feb 13 5
35 31910380 Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia. 2020 Jan 3
36 32055803 Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia. 2020 Jan 2
37 32171892 Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. 2020 Jul 1
38 32208957 Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. 2020 May 20 3
39 32296873 Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. 2020 May 5
40 32306411 Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. 2020 Oct 1
41 32380538 Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. 2020 May 12 2
42 32393603 Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis. 2020 Aug 15 3
43 32416072 Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. 2020 Jun 5
44 32530764 Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. 2020 Oct 10 2
45 32588467 Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. 2020 Nov 5
46 32601974 Treatment of Relapsed Acute Myeloid Leukemia. 2020 Jun 29 3
47 32716208 Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study. 2020 Sep 1 6
48 32758465 Ivosidenib for advanced IDH1-mutant cholangiocarcinoma. 2020 Aug 1
49 32758466 Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply. 2020 Aug 1
50 32808831 Evaluating ivosidenib for the treatment of acute myeloid leukemia. 2020 Dec 3